Posted on September 19, 2024
What’s This About? 🔍
A promising new study examined the combination of two drugs, Rogaratinib Plus Atezolizumab,
in patients with locally advanced or metastatic bladder cancer,
who cannot receive Cisplatin treatment (standard chemotherapy).
The study focused on patients whose tumors express high levels of a special protein called FGFR.
How Does It Work? 💊
Rogaratinib is a drug that blocks FGFR receptors involved in cancer growth,
and Atezolizumab is an immunotherapy drug that helps the immune system fight cancer cells.
The combination is designed to enhance treatment effectiveness.
What Did They Find? 📊
The results are particularly impressive! ✨
- 53.8% of patients responded to the combination therapy
- 15% of patients achieved complete response (tumor disappearance)!
- The treatment was effective even in patients with low levels of PD-L1 marker (which typically predicts poor response to immunotherapy)
- Side effects were manageable, with the most common being diarrhea (62%) and high phosphate levels in blood (51%)
Why Is This Important? 💫
This is especially significant news for patients who cannot receive standard chemotherapy treatment!
The new combination offers a promising treatment option that can help a broad group of patients.
Remember, we’re here for you ❤
Locating and supporting access to innovative drugs and advanced treatments for metastatic and stage 4 patients worldwide 🌍
Share this post – it might help someone you know! 🤝
Yours,
Nir Erez / Trial-In Pharma 👨⚕
